The uptake kinetics and immunotoxic effects of microcystin-LR in human and chicken peripheral blood lymphocytes in vitro.
Microcystin-LR is a cyanobacterial heptapeptide that presents acute and chronic hazards to animal and human health. We investigated the influence of this toxin on human and chicken immune system modulation in vitro. Peripheral blood lymphocytes were treated with microcystin-LR at environmentally relevant doses of 1, 10 and 25 microg/ml for 12, 24, 48, 72 h (for proliferation assay cells were treated for 72 h). T-cell and B-cell proliferation as well as apoptosis and necrosis were determined in human and chicken samples. IL-2 and IL-6 production by human lymphocytes also was measured. In addition, uptake kinetics of microcystin-LR into human and chicken peripheral blood lymphocytes were calculated by Liquid Chromatography (LS) /Mass Spectrometry (MS) analysis. At the highest dose microcystin-LR decreased T-cell proliferation and all doses of microcystin-LR inhibited B-cell proliferation. The frequency of apoptotic and necrotic cells increased in a dose and time-dependent manner. Human lymphocytes responded to stimulation with microcystin-LR by increased production of IL-6 and decreased production of IL-2. Human lymphocytes were able to uptake from 0.014 to 1.663 microg/ml and chicken lymphocytes from 0.035 to 1.733 microg/ml of the microcystin-LR added to the cultures, depending on the treatment time and dose. In conclusion, microcystin-LR acted as an immunomodulator in cytokine production and down-regulated lymphocyte functions by induction of apoptosis and necrosis. However, further studies dealing with the influence of microcystin-LR on expression cytokine genes and transcription factors are necessary to confirm these hypotheses.
Lankoff
Anna
A
Department of Radiobiology and Immunology, Institute of Biology, Pedagogical University, Swietokrzyska Academy, 25-406 Kielce, ul. Swietokrzyska, 1525 425, Poland. alankoff@pu.kielce.pl
Carmichael
Wayne W
WW
Grasman
Keith A
KA
Yuan
Moucun
M
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002853:Chromatography, Liquid; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism*; D008387:Marine Toxins / Q000493:pharmacokinetics* / Q000633:toxicity*; D013058:Mass Spectrometry / Q000379:methods; D052998:Microcystins; D009336:Necrosis; D010456:Peptides, Cyclic / Q000493:pharmacokinetics* / Q000633:toxicity*; D010718:Phosphatidylserines / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects
D007376:Interleukin-2; D015850:Interleukin-6; D008387:Marine Toxins; D052998:Microcystins; D010456:Peptides, Cyclic; D010718:Phosphatidylserines; C057862:cyanoginosin LR